WithdrawnNCT05921929
First-in-human FENM study in healthy adults
The withdrawn trial planned to study the safety and processing of a single oral dose.
Medication studyAges 18–45BelgiumDepression
Understand this study
Who could participate?
This withdrawn early-phase study was designed for healthy adult volunteers aged 18 to 45.
What does the protocol involve?
The protocol planned one oral dose of FENM per participant to study safety and how the body processes the drug.
- Listed locations
- LiègeSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: May 2, 2024
- Recruitment status
- Withdrawn
- Enrollment listed in the registry
- 0
- Sponsor
- ReST Therapeutics
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- Belgium
- Age range
- From 18 Years to 45 Years
- Official registry ID
- NCT05921929
- Official title
Show the full official title
Safety and Pharmacokinetics of a Novel NMDA Receptor Antagonist Against Brain Related Diseases in Healthy Adult Volunteers: First-in-human, Phase I, Single Dose-escalating, Open Label Study
Recruitment & locations
WithdrawnThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Liège
Next step · Check the official record for the status. You can also look for open studies on HopeStage.
Updated by the registry
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is ReST Therapeutics.
Does this study involve medication?
Yes. The study involves medication, including Fluoroethylnormemantine (FENM).
Who could participate?
This withdrawn early-phase study was designed for healthy adult volunteers aged 18 to 45.
Is this study still recruiting?
The registry lists this study as withdrawn.
